http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2001316389-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_850a17186ff51f03c607cf42a534a635 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
| filingDate | 2001-02-28^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbe6f3bc4018159826133e83001409ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1af230fddc3afd18116e749656499c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebfff01fa8f2e0b72b7e4c8adbcc0a14 |
| publicationDate | 2001-11-13^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2001316389-A |
| titleOfInvention | Pyrrolopyridinium derivatives |
| abstract | PROBLEM TO BE SOLVED: To provide a novel AGE, an antibody prepared using the AGE as a hapten, a test method for measuring the AGE, a diabetes-related disease, renal failure, dialysis complications, aging, and aging. Accompanying diseases, To provide a method for evaluating the efficacy of a drug effective for Alzheimer's disease and the like. SOLUTION: The pyrrolopyridinium derivative of the present invention is a compound represented by the following general formula (I), (II) or (III). Embedded image Embedded image Embedded image [In the formula, R ′ and R ″ are the same or different and each represents an amino group, an amino group having a protecting group and / or an alkyl group optionally having a carboxyl group.] The pyrrolopyridinium derivative of the present invention is Conventional A Novel AG having a completely new structural skeleton different from GE In addition to E, it is considered to be a cross-linking substance generated through both saccharification reaction and oxidation reaction in view of its characteristic structure, and further has a hemiacetal structure having reactivity in the molecule. It can be expected to have a different utility similar to that of the above AGEs, and is very useful in the field where various AGEs are required. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020045646-A1 |
| priorityDate | 2000-02-29^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 65 of 65.